Last updated: 2 July 2024 at 6:57pm EST

Patrick Lamy Net Worth




The estimated Net Worth of Patrick Lamy is at least $488 ezer dollars as of 11 June 2024. Patrick Lamy owns over 569 units of Akero Therapeutics Inc stock worth over $475,558 and over the last 2 years Patrick sold AKRO stock worth over $12,882.

Patrick Lamy AKRO stock SEC Form 4 insiders trading

Patrick has made over 1 trades of the Akero Therapeutics Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently Patrick sold 569 units of AKRO stock worth $12,882 on 11 June 2024.

The largest trade Patrick's ever made was selling 569 units of Akero Therapeutics Inc stock on 11 June 2024 worth over $12,882. On average, Patrick trades about 142 units every 0 days since 2023. As of 11 June 2024 Patrick still owns at least 18,562 units of Akero Therapeutics Inc stock.

You can see the complete history of Patrick Lamy stock trades at the bottom of the page.



What's Patrick Lamy's mailing address?

Patrick's mailing address filed with the SEC is C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BLVD, SUITE 350, SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Akero Therapeutics Inc

Over the last 5 years, insiders at Akero Therapeutics Inc have traded over $146,260,704 worth of Akero Therapeutics Inc stock and bought 4,870,000 units worth $104,250,550 . The most active insiders traders include Group, Llc Green Jeremy Red..., Trust Blue Horizon Enterpri... és G. Walmsley Graham. On average, Akero Therapeutics Inc executives and independent directors trade stock every 11 days with the average trade being worth of $1,642,344. The most recent stock trade was executed by Jonathan Young on 3 September 2024, trading 5,000 units of AKRO stock currently worth $133,600.



What does Akero Therapeutics Inc do?

akero therapeutics is developing best-in-class medicines that restore metabolic balance to treat non-alcoholic steatohepatitis (nash) and other serious metabolic diseases. akero's lead clinical program, akr-001, is a long-acting fc fusion modified fgf21 protein and potential best-in-class treatment for nash. akr-001 builds upon two decades of work on fgf21 biology. it is designed to affect both the liver and adipose tissue, reducing liver fat and suppressing inflammation and fibrosis.



What does Akero Therapeutics Inc's logo look like?

Akero Therapeutics Inc logo

Complete history of Patrick Lamy stock trades at Akero Therapeutics Inc

Dátum
#
Cég
Az érdekelt
Trans.
Tranzakció
Részvények száma Ár per részvény Teljes ár Részvények szíma után Forrás
11 Jun 2024 Patrick Lamy
Senior VP és Commercial Strategy
Eladás 569 $22.64 $12,882
11 Jun 2024
18,562


Akero Therapeutics Inc executives and stock owners

Akero Therapeutics Inc executives and other stock owners filed with the SEC include: